TY - JOUR
T1 - Delivering affordable cancer care in high-income countries
AU - Sullivan, Richard
AU - Peppercorn, Jeffrey
AU - Sikora, Karol
AU - Zalcberg, John
AU - Meropol, Neal J.
AU - Amir, Eitan
AU - Khayat, David
AU - Boyle, Peter
AU - Autier, Philippe
AU - Tannock, Ian F.
AU - Fojo, Tito
AU - Siderov, Jim
AU - Williamson, Steve
AU - Camporesi, Silvia
AU - McVie, J. Gordon
AU - Purushotham, Arnie D.
AU - Naredi, Peter
AU - Eggermont, Alexander
AU - Brennan, Murray F.
AU - Steinberg, Michael L.
AU - De Ridder, Mark
AU - McCloskey, Susan A.
AU - Verellen, Dirk
AU - Roberts, Terence
AU - Storme, Guy
AU - Hicks, Rodney J.
AU - Ell, Peter J.
AU - Hirsch, Bradford R.
AU - Carbone, David P.
AU - Schulman, Kevin A.
AU - Catchpole, Paul
AU - Taylor, David
AU - Geissler, Jan
AU - Brinker, Nancy G.
AU - Meltzer, David
AU - Kerr, David
AU - Aapro, Matti
N1 - Funding Information:
The FDA requires drugs to show efficacy in a clinical trial before approval for routine use. Although medical device approval can require a clinical trial, the most common pathway for approval of radiation oncology technologies is the so-called 510K process. This process requires only that the device vendor shows the device to be safe for patient use. Therefore, although the safety and mechanical dependability aspect of the 510K process can be daunting, the process does not require that the device show efficacy or an enhanced health outcome beyond its predicate device in a controlled clinical trial. By contrast with drug development and approval for use, which is supported by an extensive and costly clinical trial infrastructure funded by a well capitalised pharmaceutical industry, no comparable system exists in the technology arena.
PY - 2011/9
Y1 - 2011/9
N2 - The burden of cancer is growing, and the disease is becoming a major economic expenditure for all developed countries. In 2008, the worldwide cost of cancer due to premature death and disability (not including direct medical costs) was estimated to be US$895 billion. This is not simply due to an increase in absolute numbers, but also the rate of increase of expenditure on cancer. What are the drivers and solutions to the so-called cancer-cost curve in developed countries? How are we going to afford to deliver high quality and equitable care? Here, expert opinion from health-care professionals, policy makers, and cancer survivors has been gathered to address the barriers and solutions to delivering affordable cancer care. Although many of the drivers and themes are specific to a particular field-eg, the huge development costs for cancer medicines-there is strong concordance running through each contribution. Several drivers of cost, such as over-use, rapid expansion, and shortening life cycles of cancer technologies (such as medicines and imaging modalities), and the lack of suitable clinical research and integrated health economic studies, have converged with more defensive medical practice, a less informed regulatory system, a lack of evidence-based sociopolitical debate, and a declining degree of fairness for all patients with cancer. Urgent solutions range from re-engineering of the macroeconomic basis of cancer costs (eg, value-based approaches to bend the cost curve and allow cost-saving technologies), greater education of policy makers, and an informed and transparent regulatory system. A radical shift in cancer policy is also required. Political toleration of unfairness in access to affordable cancer treatment is unacceptable. The cancer profession and industry should take responsibility and not accept a substandard evidence base and an ethos of very small benefit at whatever cost; rather, we need delivery of fair prices and real value from new technologies.
AB - The burden of cancer is growing, and the disease is becoming a major economic expenditure for all developed countries. In 2008, the worldwide cost of cancer due to premature death and disability (not including direct medical costs) was estimated to be US$895 billion. This is not simply due to an increase in absolute numbers, but also the rate of increase of expenditure on cancer. What are the drivers and solutions to the so-called cancer-cost curve in developed countries? How are we going to afford to deliver high quality and equitable care? Here, expert opinion from health-care professionals, policy makers, and cancer survivors has been gathered to address the barriers and solutions to delivering affordable cancer care. Although many of the drivers and themes are specific to a particular field-eg, the huge development costs for cancer medicines-there is strong concordance running through each contribution. Several drivers of cost, such as over-use, rapid expansion, and shortening life cycles of cancer technologies (such as medicines and imaging modalities), and the lack of suitable clinical research and integrated health economic studies, have converged with more defensive medical practice, a less informed regulatory system, a lack of evidence-based sociopolitical debate, and a declining degree of fairness for all patients with cancer. Urgent solutions range from re-engineering of the macroeconomic basis of cancer costs (eg, value-based approaches to bend the cost curve and allow cost-saving technologies), greater education of policy makers, and an informed and transparent regulatory system. A radical shift in cancer policy is also required. Political toleration of unfairness in access to affordable cancer treatment is unacceptable. The cancer profession and industry should take responsibility and not accept a substandard evidence base and an ethos of very small benefit at whatever cost; rather, we need delivery of fair prices and real value from new technologies.
UR - http://www.scopus.com/inward/record.url?scp=80053238941&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(11)70141-3
DO - 10.1016/S1470-2045(11)70141-3
M3 - Review article
C2 - 21958503
AN - SCOPUS:80053238941
SN - 1470-2045
VL - 12
SP - 933
EP - 980
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 10
ER -